ArticleFrontiers in endocrinology2026
Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto's thyroiditis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid cancer represents the most prevalent malignancy of the endocrine system, with papillary thyroid carcinoma (PTC) accounting for approximately 90% of cases. Hashimoto's thyroiditis (HT) is a common benign thyroid disorder, frequently associated with structural alterations in thyroid morphology. Evidence indicated that HT may be a risk factor for the development of PTC. Exosomes promote intercellular communication by transferring proteins, mRNAs, micro-RNAs (miRNAs), and lipids to recipient cells, rendering them potential sources of disease-specific biomarkers. Methods: This study employed an integrative approach, combining exosome isolation, proteomics, and bioinformatics to identify plasma-derived exosomal biomarkers associated with PTC in the context of HT. Plasma samples were obtained from three patients each with PTC, PTC associated with HT (PTC-W), HT, and healthy controls (HCs). Exosomal proteins were extracted and analyzed using label-free quantitative proteomics. Results: A total of 45 differentially expressed proteins (DEPs) were identified between PTC-W and HT. Functional annotation and enrichment analyses revealed that these DEPs were predominantly implicated in extracellular matrix (ECM)-receptor interactions and immune response pathways. Subsequent validation via parallel reaction monitoring (PRM) confirmed that SVEP1 and IGKV3-7 exhibited consistent and statistically significant expression levels across discovery and validation phases. Discussion: These results highlight SVEP1 and IGKV3-7 as promising plasma exosomal biomarkers for PTC in patients with HT, providing mechanistic insights into the progression from HT to PTC and potential utility for non-invasive clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.